Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
AK Medical Holdings Limited (1789.HK)
HKD5.70
+0.24 (+4.40%)
CN HKSE Healthcare Medical - Devices
Address
Xingye Building 102200
Beijing, CN
Beijing, CN
CEO
Zhijiang Li
Website
ak-medical.net
IPO
2017-12-20
ISIN KYG020141019
Description
AK Medical Holdings Limited, an investment holding enterprise, specializes in the research, development, production, and worldwide commercialization of orthopedic joint implants and related medical devices under the AK Medical brand. Its comprehensive product offerings encompass conventional knee, hip, and spine replacement implants, as well as advanced 3D-printed solutions like hip implants, artificial vertebral bodies, and spinal interbody cages. The company further expands its operations by distributing orthopedic products from third-party manufacturers and by fabricating surgical instruments and medical irrigators. Its diverse client base spans distributors, hospitals, physicians, surgeons, and directly serves patients. Established in Beijing, People's Republic of China, in 2003, AK Medical Holdings Limited functions as a subsidiary of Ximalaya Limited.
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
HKD5.70
+0.24 (+4.40%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
6M
Beta
-0.39
Float Shares
544.94M
Free Float %
49.1%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +0.00% | -2.34% | -7.14% | -9.16% | +5.22% | +2.63% | -1.35% | -21.79% | -58.09% | +121.59% | +121.59% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Price Targets & DCF
Current price
5.70
DCF (Unlevered)
33.84
+493.8%
DCF (Levered)
53.18
+833.0%
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
Ratings Trend (MoM)
100% Bullish
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 6 | 0 |
| Hold | 0 | -1 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Quality scores
Altman Z-Score
6.53
Safe zone
Piotroski F-Score
8 / 9
Strong
MOAT Score
5 / 10
Developing
Composite Rating
A
Overall Score
4 / 5
High
DCF Score
5 / 5
High
ROE Score
4 / 5
High
ROA Score
5 / 5
High
D/E Score
3 / 5
Medium
P/E Score
2 / 5
Medium
P/Book Score
3 / 5
Medium
Operational MOAT
✗ Below peers
-
Revenue growth Medical - Devices: +11.2%+10.1% Q4'25: +81.0% (vs Q4'23)
-
EPS growth Medical - Devices: +28.5%+25.0% Q4'25: +268.7% (vs Q4'23)
-
FCF margin FCF growth · Medical - Devices: +30.9%+18.5% Q4'25: +25.0% (vs Q4'23)
-
EBIT margin Medical - Devices: +6.2%+25.2% ★ Q4'25: +26.2% (vs Q4'23)
-
ROIC Medical - Devices: +3.3%+20.2% ★ Q4'25: +44.5% (vs Q4'23)
-
Share dilution Medical - Devices: 0.0%+0.1% Q4'25: +0.3% (vs Q4'23)
-
Debt / EBITDA Net debt/EBITDA · Medical - Devices: -0.35×0.31× ★ Q4'25: 0.15× (vs Q4'23)
Valuation Multiples
From
To
Price Forecast (3Y)
From
To
Theoretical Return — If Invested Today
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
Consensus Estimates
| Metric |
Dec 2017 actual |
Dec 2018 actual |
Dec 2019 actual |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 5 Rev. Ana. 4 EPS Ana. |
Dec 2027 5 Rev. Ana. 4 EPS Ana. |
Dec 2028 4 Rev. Ana. 4 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
372.70M
est: 420.14M (-11.3%)
|
600.56M
est: 667.11M (-10.0%)
|
926.71M
est: 1.04B (-10.7%)
|
1.04B
est: 1.30B (-20.5%)
|
761.44M
est: 903.65M (-15.7%)
|
1.05B
est: 1.19B (-11.3%)
|
1.09B
est: 1.03B (+6.7%)
|
1.35B
est: 1.36B (-0.7%)
|
1.48B
est: 1.51B (-1.9%)
|
1.73B
1.71B – 1.76B
+14.7% YoY
|
1.95B
1.90B – 2.01B
+12.3% YoY
|
2.17B
2.14B – 2.23B
+11.7% YoY
|
| EBITDA |
137.13M
est: 129.74M (+5.7%)
|
195.26M
est: 206.01M (-5.2%)
|
341.38M
est: 302.32M (+12.9%)
|
438.41M
est: 378.80M (+15.7%)
|
184.33M
est: 523.90M (-64.8%)
|
322.87M
est: 759.46M (-57.5%)
|
323.34M
est: 374.49M (-13.7%)
|
371.66M
est: 495.24M (-25.0%)
|
465.33M
est: 551.95M (-15.7%)
|
633.09M
626.16M – 642.94M
+14.7% YoY
|
710.94M
694.31M – 733.93M
+12.3% YoY
|
793.79M
779.89M – 813.15M
+11.7% YoY
|
| EBIT |
124.89M
est: 98.82M (+26.4%)
|
174.52M
est: 156.90M (+11.2%)
|
322.07M
est: 260.77M (+23.5%)
|
377.89M
est: 332.52M (+13.6%)
|
110.17M
est: 459.89M (-76.0%)
|
242.46M
est: 666.66M (-63.6%)
|
232.40M
est: 351.91M (-34.0%)
|
300.78M
est: 464.47M (-35.2%)
|
373.88M
est: 518.67M (-27.9%)
|
594.91M
588.40M – 604.17M
+14.7% YoY
|
668.07M
652.44M – 689.67M
+12.3% YoY
|
745.92M
732.87M – 764.12M
+11.7% YoY
|
| Net Income |
105.38M
est: 174.58M (-39.6%)
|
144.94M
est: 178.60M (-18.8%)
|
266.99M
est: 220.73M (+21.0%)
|
314.01M
est: 281.37M (+11.6%)
|
92.62M
est: 389.16M (-76.2%)
|
204.77M
est: 211.31M (-3.1%)
|
182.10M
est: 175.61M (+3.7%)
|
273.93M
est: 269.36M (+1.7%)
|
339.09M
est: 335.81M (+1.0%)
|
401.67M
366.23M – 437.10M
+19.6% YoY
|
475.65M
411.06M – 540.24M
+18.4% YoY
|
523.11M
463.67M – 582.55M
+10.0% YoY
|
| SGA |
106.62M
est: 126.45M (-15.7%)
|
197.00M
est: 200.79M (-1.9%)
|
267.54M
est: 300.02M (-10.8%)
|
237.12M
est: 281.95M (-15.9%)
|
292.66M
est: 389.95M (-24.9%)
|
298.42M
est: 565.28M (-47.2%)
|
352.25M
est: 319.41M (+10.3%)
|
384.86M
est: 421.56M (-8.7%)
|
417.58M
est: 470.76M (-11.3%)
|
539.96M
534.05M – 548.36M
+14.7% YoY
|
606.36M
592.17M – 625.97M
+12.3% YoY
|
677.02M
665.17M – 693.54M
+11.7% YoY
|
| EPS |
0.14
est: 0.16 (-10.3%)
|
0.14
est: 0.16 (-12.3%)
|
0.26
est: 0.27 (-4.1%)
|
0.28
est: 0.38 (-27.0%)
|
0.08
est: 0.12 (-32.2%)
|
0.18
est: 0.20 (-7.8%)
|
0.16
est: 0.16 (+1.6%)
|
0.25
est: 0.24 (+5.7%)
|
0.30
est: 0.30 (+0.0%)
|
0.37
0.33 – 0.39
+24.0% YoY
|
0.43
0.37 – 0.48
+16.3% YoY
|
0.49
0.41 – 0.52
+12.3% YoY
|
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-29 | A | 4/5 | 5/5 | 4/5 | 5/5 | 3/5 | 2/5 | 3/5 |
| 2026-05-28 | A | 4/5 | 5/5 | 4/5 | 5/5 | 3/5 | 2/5 | 3/5 |
| 2026-05-27 | A | 4/5 | 5/5 | 4/5 | 5/5 | 3/5 | 2/5 | 3/5 |
| 2026-05-26 | A | 4/5 | 5/5 | 4/5 | 5/5 | 3/5 | 2/5 | 3/5 |
| 2026-05-22 | A | 4/5 | 5/5 | 4/5 | 5/5 | 3/5 | 2/5 | 3/5 |
| 2026-05-21 | A | 4/5 | 5/5 | 4/5 | 5/5 | 3/5 | 2/5 | 3/5 |
| 2026-05-20 | A | 4/5 | 5/5 | 4/5 | 5/5 | 3/5 | 2/5 | 3/5 |
| 2026-05-19 | A | 4/5 | 5/5 | 4/5 | 5/5 | 3/5 | 2/5 | 3/5 |
| 2026-05-18 | A | 4/5 | 5/5 | 4/5 | 5/5 | 3/5 | 2/5 | 3/5 |
| 2026-05-15 | A | 4/5 | 5/5 | 4/5 | 5/5 | 3/5 | 2/5 | 3/5 |
| 2026-05-14 | A | 4/5 | 5/5 | 4/5 | 5/5 | 3/5 | 2/5 | 3/5 |
| 2026-05-13 | A | 4/5 | 5/5 | 4/5 | 5/5 | 3/5 | 3/5 | 3/5 |
| 2026-05-12 | A | 4/5 | 5/5 | 4/5 | 5/5 | 3/5 | 3/5 | 3/5 |
| 2026-05-11 | A | 4/5 | 5/5 | 4/5 | 5/5 | 3/5 | 3/5 | 3/5 |
| 2026-05-08 | A | 4/5 | 5/5 | 4/5 | 5/5 | 3/5 | 3/5 | 3/5 |
| 2026-05-07 | A | 4/5 | 5/5 | 4/5 | 5/5 | 3/5 | 3/5 | 3/5 |
| 2026-05-06 | A | 4/5 | 5/5 | 4/5 | 5/5 | 3/5 | 3/5 | 3/5 |
| 2026-05-05 | A | 4/5 | 5/5 | 4/5 | 5/5 | 3/5 | 3/5 | 3/5 |
| 2026-05-04 | A | 4/5 | 5/5 | 4/5 | 5/5 | 3/5 | 3/5 | 3/5 |
| 2026-04-30 | A | 4/5 | 5/5 | 4/5 | 5/5 | 3/5 | 3/5 | 3/5 |
| 2026-04-29 | A | 4/5 | 5/5 | 4/5 | 5/5 | 2/5 | 3/5 | 3/5 |
| 2026-04-28 | A | 4/5 | 5/5 | 4/5 | 5/5 | 2/5 | 3/5 | 3/5 |
| 2026-04-27 | A | 4/5 | 5/5 | 4/5 | 5/5 | 2/5 | 3/5 | 3/5 |
| 2026-04-24 | A | 4/5 | 5/5 | 4/5 | 5/5 | 2/5 | 3/5 | 3/5 |
| 2026-04-23 | A | 4/5 | 5/5 | 4/5 | 5/5 | 2/5 | 3/5 | 3/5 |
| 2026-04-22 | A | 4/5 | 5/5 | 4/5 | 5/5 | 2/5 | 3/5 | 3/5 |
| 2026-04-21 | A | 4/5 | 5/5 | 4/5 | 5/5 | 2/5 | 3/5 | 3/5 |
| 2026-04-20 | A | 4/5 | 5/5 | 4/5 | 5/5 | 2/5 | 3/5 | 3/5 |
| 2026-04-17 | A | 4/5 | 5/5 | 4/5 | 5/5 | 2/5 | 3/5 | 3/5 |
| 2026-04-16 | A | 4/5 | 5/5 | 4/5 | 5/5 | 2/5 | 3/5 | 3/5 |
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
797.97M
OE per share TTM
0.71
Owner's Yield
12.20%
Maintenance CapEx ratio
66.07%
Maint CapEx / Avg PPE
41.9%
Ownership Overview
Ownership breakdown
Ownership breakdown not available.
At a glance
Institutional holders
—
Total invested
—
Insider transactions (90d)
0
Beneficial owners (>5%)
0
Beneficial owners (>5%)
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional ownership trend
Institutional history not available.
Top institutional holders
Top holders not available.
ETF Ownership
Top ETFs holding this stock
Held by 64 ETFs in our universe
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | Sophus Capital Emerging Market Small Cap ETF EMSC | 1.09% | 484.9K | 0.85% |
| 2 | iShares MSCI China Small-Cap ETF ECNS | 0.24% | 154.6K | 0.59% |
| 3 | Global X - Aging Population ETF AGNG | 0.22% | 191.6K | 0.50% |
| 4 | iShares MSCI AC Far East ex-Japan Small Cap UCITS ETF ISFE.L | 0.03% | 21.4K | 0.74% |
| 5 | WisdomTree Emerging Markets SmallCap Dividend UCITS ETF DGSD.L | 0.03% | 12.3K | 0.54% |
| 6 | State Street SPDR S&P Emerging Markets Small Cap ETF EWX | 0.03% | 196.1K | 0.65% |
| 7 | State Street SPDR MSCI Emerging Markets Small Cap UCITS ETF EMSD.L | 0.03% | 164.7K | 0.55% |
| 8 | WisdomTree Emerging Markets SmallCap Dividend Fund DGS | 0.03% | 448.8K | 0.58% |
| 9 | iShares MSCI Emerging Markets Small-Cap ETF EEMS | 0.02% | 93.2K | 0.72% |
| 10 | Avantis Emerging Markets Small Cap Equity ETF AVEE | 0.02% | 22.8K | 0.42% |
Insider Activity
Insider Activity — Latest Quarter
No insider activity available.
Insider buys vs sells (history)
Insider history not available.
Recent insider transactions
No recent insider transactions.
Executive team
Top executives
EBIT / Employee
393.6K
Shares Outstanding
1.11B
Executive compensation
Executive compensation (annual)
Executive compensation not available.
CEO compensation breakdown
No CEO compensation history available.
Proxy statements
Proxy statements (DEF 14A)
No proxy statements available for this company yet.
Recent SEC filings
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Zhijiang Li | Chairman & Chief Executive Officer | 2M | male |
| Chaoyang Zhang | Senior Vice President & Executive Director | 2M | male |
| Bin Zhang | Senior Vice President & Executive Director | 2M | female |
| Xiaohong Zhao | Vice President & Executive Director | 2M | female |
| Rongkun Ma | Company Secretary | — | female |
| Hanzhong Sun | Vice President of Human Resources | — | male |
| Caimei Wang | Chief Technology Officer of AK Medical Group | — | female |
| Aiguo Liu | VP & Head of the Compliance | — | female |
| Kun Liang | Chief Financial Officer | — | female |
ESG Score History
No data available for this company.
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 1789.HK
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
